Progetti PNNR

  • PNRR 1 Bando, "Dissecting the role of tau in ovarian carcinoma pathogeniesis and drug resistance”, Principal Investigator Dott.ssa Amalia Azzariti
  • PNRR 1 Bando, "Development and validation of a biomedical device for the detection, characterization and removal of Circulating Tumor Cells from the peripheral blood of patients for the treatment and diagnosis of cancer-EVOLUTION", Principal Investigator Dott.ssa Brunella Pilato
  • PNRR 1 Bando, A multi-omic approach for gene fusion detection in hematological malignancies: towards improved diagnostic screening and therapeutic targeting -FUSION-TARGET”, Principal Investigator Dott. Giacomo Volpe
  • PNRR 1 Bando, “A multiomics approach to identify signatures of response and resistance to immunotherapy in R/R Diffuse Large B-cell Lymphoma”, Principal Investigator Dott. Attilio Guarini
  • PNRR 1 Bando, “Analyses of HPV and host body fluid biomarkers as noninvasive strategy for detection of head and neck cancer relapse”, Principal Investigator Dott.ssa Raffaella Massafra
  • PNRR 1 Bando, Leukemic cell and microenvironment interactions as the culprit of chronicity in CLL, Principal Investigator Dott.ssa Carla Minoia
  • PNRR 1 Bando, “Identification of common pathogenic mechanisms driving quamous cell carcinomas of the anogenital tract and head&neck region to develop overarching therapeutic strategies”, Principal Investigator Dott. Oronzo Brunetti
  • PNRR 1 Bando, “Systematic reclassification of Variants of Unknown Significance in cancer-predisposing genes through machine learning applied to CRISP-based functional screens”, Principal Investigator Dott.ssa Stefania Tommasi
  • PNRR 1 Bando, "Cancer of unknown primary: shifting the paradigm from undefined heterogeneous malignancies to a new tumor type arising from cancer stem cells by specific pathogenetic mechanisms and targetable dysregulated pathways", Principal Investigator Dott. Alfredo Zito. 
  • PNRR 2 Bando, NECTIN-1 AS A NEW SPECIFICA DISGNOSTIC AND THERAPEUTIC MARKER FOR POLYMORPHONUCLEAR MYELOID-DERIVED SUPPRESSOR CELLS (PMN-MDSC), Principal Investigator Dott.ssa Antonella Argentiero
  • PNRR 2 Bando, Artificial intelligence and compUtational biology  for pRedicting nOvel immunotheRApeutic strategies in microsatellite stability colon cancer patients – AURORA, Principal Investigator Dott.ssa Amalia Azzariti
  • PNRR 2 Bando, "NANOPARTICLE ENABLED BLOOD TEST FOR DETECTION OF PANCREATIC CANCER IN INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS (IPMNs)", Principal Investigator Dott. Oronzo Brunetti
  • PNRR 2 Bando, "LongitudInal monItoring For the Earliest and BEst management for pLeural mesoThelioma", Principal Investigator Dott. Annamaria Catino
  • PNRR 2 Bando, "MCNT- Prevenzione Early diagnosis of high-grade  serous epithelial ovarian cancer through the analysis of DNA derived from Pap test smear", Principal Investigator Dott. Gennaro Cormio
  • PNRR 2 Bando, DISCOVERY OF NEW ANTI-CANCER IMMUNOMODULATORS TO MAKE HIGH RISK NEUROBLASTOMA PATIENTS RESPONSIVE TO IMMUNOTHERAPY APPROACHES, Principal Investigator Dott.ssa Letizia Porcelli
  • PNRR 2 Bando, Inhibition of vegfr-1 with innovative biologics that target the tumor, tumor-associated vessels and immunosuppresive microenvironment for melanoma treatment, Dott.ssa Simona Serratì
  • PNRR 2 Bando, Scale-up the indistrial developement of cd99-null extracellular vescicles (evs) as therapeutic tools by using ewing sarcoma as prototype (start), Principal Investigator Dott.ssa Stefania Tommasi
  • PNRR 2 Bando, Integrated BCR signaling and genomic/transcriptomic to identify patients with MCL failing BTK-inhibitors, Principal Investigator Dott.ssa Mariella Vegliante
  • PNRR 2 Bando, Developing a Biobank network among major sarcoma treatment centers to improve biomedical research, Principal Investigator Dott. Sabino Strippoli
  • PNRR 2 Bando, "LIquid Biopsy implEmentation in the management of Rare Tumors associated with hereditarY syndromes (LIBERTY)", Principal Investigator Dott.ssa Margherita Patruno

Documenti e Modulistica